SBIO vs XBI

SBIOCALPS Medical Breakthroughs ETF

XBIAState Street SPDR S&P Biotech ETF

In short

SBIO SBIO goes at biotech through a purpose-built medical breakthroughs index instead of the household benchmarks, spreading roughly 100 drug developers across one basket. A specialist route, priced at the category's middle.

XBI Biotech's great leveler. Its index weights roughly 160 US biotechs near-equally, so a clinical-stage minnow carries about as much as a megacap. Live since 2006 and one of the most heavily traded funds in the sector.

Stated mandate

SBIO The fund seeks investment results that generally track, before fees and expenses, the performance of the S-Network Medical Breakthroughs Index (PMBI).

XBI The fund seeks to track, before fees and expenses, the total return performance of the S&P Biotechnology Select Industry Index.

Why people hold it

• SBIO Tracks the S-Network Medical Breakthroughs Index, a dedicated rules-based basket rather than the standard biotech benchmarks most funds in the group follow.
• Roughly 100 holdings, so no single drug readout carries the whole fund.
• The 0.50% expense ratio sits right at the median for biotech and genomics funds. No premium charged for the narrower mandate.
• Trading since 2014, giving it a decade-plus of live operating history through several biotech cycles.

• XBI Modified equal weighting spreads exposure across roughly 160 biotechs instead of a handful of giants, so small drug developers actually move the fund.ssga.com
• 0.35% a year sits below the typical fee in its biotech peer group, which is unusual for a specialist sleeve this narrow.
• Among the most heavily traded funds in biotech and multi-billion-dollar in size, so getting in and out is rarely the hard part.
• A 2006 launch from State Street's SPDR line, meaning it has traded through several biotech booms and busts rather than one hot cycle. Pays quarterly.

Worth knowing

• SBIO Thinly traded next to the giants of the category, so spreads and limit orders matter more here than with the household names.
• Several funds in the same biotech cohort screen stronger overall, and some cost less: IBBQ at 0.19% and XBI at 0.35% versus SBIO's 0.50%.
• Not an income vehicle. Whatever this fund does, it does through the share prices of the drug developers it holds.

• XBI Equal weighting leans hard on smaller, clinical-stage names where a single trial readout moves a stock, so swings run deeper than cap-weighted rivals like IBB.ssga.comnasdaqomx.com
• Not the cheapest ticket on the shelf: Invesco's IBBQ charges 0.19% against XBI's 0.35%.
• One US industry only, drawn from the biotechnology segment of the S&P Total Market Index, so it can drift a long way from the broad market either direction.ssga.com

Full SBIO profile⁠

Full XBI profile⁠